Abstract
Autologous stem cell mobilization (ASCM) is conventionally done using high-dose CY plus granulocyte colony-stimulating factor (G). It is important to examine the outcomes, toxicity profile and costs of ASCM associated with CY+G. A retrospective study was conducted in 236 patients with myeloma or lymphoma undergoing ASCM with CY+G. An ideal outcome was defined as ⩾2 × 106 CD34+ cells/kg collected on the planned day of collection in 1 or 2 apheresis without a negative clinical event. The total cost of ASCM including clinical events, were reported based on Medicare part-B physician, laboratory and ancillary fee schedule. ASCM was successful in 213 (90%) patients, but an ideal outcome was seen in only 50 (20%) patients. Median (interquartile range, IQR) total cost of CY+G stem cells mobilization was $10 605 ($9230–$14 540). Ideal outcomes were associated with lower costs compared with non-ideal outcomes (median (IQR), $9914 ($8743–$11 168) versus $11232 ($9292–$15 518) respectively, P<0.001). The median (IQR) cost of non-ideal outcome was higher among lymphoma patients ($12 293 ($9578–$16 268)) compared with myeloma patients ($10 388 ($9355–$14 360) (P=0.04). Although mobilization success is eventually realized with CY+G, it has a low rate of ideal outcome, associated with significant adverse events and costs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bensinger W, DiPersio JF, McCarty JM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181–195.
Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316.
Ashihara E, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Shimura K et al. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J Clin Oncol 2002; 32: 135–139.
Schulman KA, Birch R, Zhen B, Pania N, Weaver CH . Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227.
Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion 2006; 46: 523–529.
Gertz MA, Wolf RC, Micallef IN, Gastineau DA . Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396–1403.
Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412–1421.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.
Tricot G, Cottler-Fox MH, Calandra G . Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63–68.
Nazha A, Cook R, Vogl D, Mangan P, Hummel K, Cunningham K et al. Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma. Blood 2009; 114: abstract 844.
Shaughnessy P, Islas-Ohlamayer M, Murphy J, Houghman M, MacPherson J, Winkler K et al. Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization. Blood 2009; 114: abstract 897.
Campen C, Armstrong E, Christian J, Hadeed S, Yeager A . Comparative Cost-effectiveness of prelixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating factor for autologous peripheral blood stem cell mobilization in patients with non-hodgkin's lymphoma. Biol Blood Marrow Transplant 2010; 16: s206.
Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K . Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351.
Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–842.
Acknowledgements
Genzyme provided financial support for Dr Jagasia (research grant) and Dr Pickard (consultant).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Rights and permissions
About this article
Cite this article
Jagasia, M., Savani, B., Neff, A. et al. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant 46, 1084–1088 (2011). https://doi.org/10.1038/bmt.2010.254
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.254
Keywords
This article is cited by
-
A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation
Bone Marrow Transplantation (2017)
-
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT
Bone Marrow Transplantation (2013)
-
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone
Bone Marrow Transplantation (2013)
-
Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease
Bone Marrow Transplantation (2012)